Evidence map›Paper›PMID 26616126›Full record

ArticleAIDS care2015

HIV serostatus disclosure in the treatment cascade: evidence from Northern Tanzania.

Jan Ostermann, Brian Pence, Kathryn Whetten, Jia Yao, Dafrosa Itemba, Venance Maro, Elizabeth Reddy, Nathan Thielman

Open access · bronzeAbstract read
In one paragraph

Article in AIDS care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Observational
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Jan Ostermanna Duke Global Health Institute , Duke University , Durham , NC , USA.
Brian Penceb Center for Health Policy and Inequalities Research , Duke University , Durham , NC , USA.
Kathryn Whettena Duke Global Health Institute , Duke University , Durham , NC , USA.
Jia Yaob Center for Health Policy and Inequalities Research , Duke University , Durham , NC , USA.
Dafrosa Itembag Tanzania Women Research Foundation , Moshi , Tanzania.
Venance Maroh Kilimanjaro Christian Medical Center , Moshi , Tanzania.
Elizabeth Reddyi Upstate Medical University , Syracuse , NY , USA.
Nathan Thielmana Duke Global Health Institute , Duke University , Durham , NC , USA.
Duke University · USKilimanjaro Christian Medical Centre · TZSUNY Upstate Medical University · USTanzania Women Research Foundation · TZ

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Coping With HIV/AIDS in TanzaniaR01MH078756 · NIMH · DUKE UNIVERSITY · PI WHETTEN, KATHRYN · 2007 to 2012
$2.9M
NIAID NIH HHS 5P30 AI064518NIAID NIH HHS P30 AI064518NIMH NIH HHS 5R01MH078756NIMH NIH HHS R01 MH078756
6 · The paper itself

Abstract

HIV serostatus disclosure plays an important role in HIV transmission risk reduction and is positively associated with HIV medication adherence and treatment outcomes. However, to date, no study has quantified the role of disclosure across the HIV treatment cascade, particularly in Sub-Saharan Africa. We used data from a cohort of HIV-infected adults in Northern Tanzania to describe associations between disclosure and engagement and retention in the HIV treatment cascade. Between 2008 and 2009, the Coping with HIV/AIDS in Tanzania (CHAT) study enrolled 260 clients newly diagnosed with HIV and 492 HIV-infected patients in established HIV care in two large HIV care and treatment centers in Northern Tanzania. Participants aged 18 and older completed annual clinical assessments and twice-annual in-person interviews for 3.5 years. Using logistic regression models, we assessed sociodemographic correlates of HIV serostatus disclosure to at least one household member, and associations between this disclosure measure and linkage to care, evaluation for antiretroviral therapy (ART) eligibility, ART coverage, and rates of undetectable HIV RNA levels during the follow-up period. Married individuals and those diagnosed earlier were more likely to have disclosed their HIV infection to at least one household member. During follow-up, HIV serostatus disclosure was associated with higher rates of linkage to care, evaluation for ART eligibility, and ART coverage. No significant association was observed with rates of undetectable viral loads. Marginal effects estimates suggest that a 10 percentage-point lower probability of linkage to care for those who did not disclose their HIV serostatus (86% vs. 96%; p = 0.035) was compounded by an 18 percentage-point lower probability of ever receiving a CD4 count (62% vs. 80%; p = .039), and a 20 percentage-point lower probability of ever receiving ART (55% vs. 75%; p = .029). If causal, these findings suggest an important role for disclosure assistance efforts across the HIV treatment cascade.

Indexed as

Medication AdherenceTruth DisclosureAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesFemaleHIV InfectionsHumansLogistic ModelsMaleTanzaniaYoung AdultARTdisclosureHIVHIV treatment cascadelinkage to careSub-Saharan Africa

Identifiers

PMID26616126
PMCPMC4685596
OpenAlexW2186661637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.